CATALYST PHARMACEUTICALS, INC. 4

Chief Strategy Officer Preethi Sundaram had 54,804 common shares, multiple option grants, and RSUs in Catalyst Pharmaceuticals, Inc. cancelled and cashed out at the $31.50-per-share merger price in connection with the acquisition by Angelini Pharma S.p.A.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chief Strategy Officer Preethi Sundaram disposed of all her equity-linked interests in connection with the cash acquisition of Catalyst by Angelini Pharma S.p.A. at $31.50 per share. A total of 54,804 shares of common stock were cancelled at the $31.50 merger price, implying cash consideration of approximately $1.73 million. In addition, multiple tranches of vested stock options with exercise prices ranging from $5.49 to $22.77 per share and expirations between 2028 and 2032, as well as several tranches of restricted stock units scheduled to vest from 2026 through 2028, were cancelled and converted into the right to receive cash equal to the per-share merger consideration less the option exercise price (for options) or the full per-share merger price (for RSUs). Following these transactions, Sundaram no longer holds Catalyst equity, and her prior option and RSU awards have been fully cashed out as part of the merger consideration rather than representing discretionary open-market trading activity.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000182

Alert Tier

6